间变性淋巴瘤激酶
肺癌
靶向治疗
医学
表皮生长因子受体
免疫疗法
精密医学
癌症
肿瘤科
药物开发
个性化医疗
生物标志物
伴生诊断
内科学
癌症研究
药品
生物信息学
病理
生物
药理学
恶性胸腔积液
生物化学
作者
Pamela Villalobos,Ignacio I. Wistuba
标识
DOI:10.1016/j.hoc.2016.08.006
摘要
The molecular characterization of lung cancer has changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it is possible to identify subsets of patients who benefit from targeted molecular therapies . The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has led to accelerated development of new drugs for lung cancer treatment. This article focuses on clinically relevant cancer biomarkers as targets for therapy and potential new targets for drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI